Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Ozempic maker Novo Nordisk NOVO.B-1.81%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

There’s a certain agreement one must enter into when deciding to have some fun. If that fun entails a night on the town, a ...

While the runaway success of Novo’s GLP-1 drugs Ozempic and Wegovy made it for a time the second ... But, it added, the recent stock price decline and rising market challenges spurred board ...

Still, while Ozempic and Wegovy have secured status ... “The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s ...